Inscrivez-vous gratuitement pour obtenir des cotations en temps réel, des graphiques interactifs, un flux d'options en direct et plus encore.

Accueil
Investir
ETFs
Etats-Unis
AMEX
State Street SPDR Portfolio Intermediate Term Treasury ETF (SPTI)
State Street SPDR Portfolio Intermediate Term Treasury ETF (SPTI) Options

State Street SPDR Portfolio Intermediate Term Treasury ETF (SPTI)

28,18

-0,12

(-0,42%)

Fermé 06 Juin 10:00PM

28,19

0,01

(0,04%)

Après les heures de négociation: 10:36PM

State Street SPDR Portfolio Intermediate Term Treasury ETF ([symbol]) Options

SPTI Flux des options

Achats

Strike	Achat	Vente	Dernier Prix	Point Médian	Var	Var %	Volume	INT OUVERT	Dernière Trans
20,00	8,10	8,30	0,00	8,20	0,00	0,00 %	0	0	-
21,00	7,10	7,30	0,00	7,20	0,00	0,00 %	0	0	-
22,00	6,10	6,30	0,00	6,20	0,00	0,00 %	0	0	-
23,00	5,10	5,30	0,00	5,20	0,00	0,00 %	0	0	-
24,00	4,10	4,30	0,00	4,20	0,00	0,00 %	0	0	-
25,00	3,10	3,30	0,00	3,20	0,00	0,00 %	0	0	-
26,00	2,15	2,30	0,00	2,225	0,00	0,00 %	0	0	-
27,00	1,15	1,30	0,00	1,225	0,00	0,00 %	0	0	-
28,00	0,20	0,35	0,00	0,275	0,00	0,00 %	0	0	-
29,00	0,00	0,10	0,00	0,00	0,00	0,00 %	0	0	-
30,00	0,00	0,10	0,00	0,00	0,00	0,00 %	0	0	-
31,00	0,00	0,10	0,00	0,00	0,00	0,00 %	0	0	-
32,00	0,00	0,10	0,00	0,00	0,00	0,00 %	0	0	-
33,00	0,00	0,10	0,00	0,00	0,00	0,00 %	0	0	-
34,00	0,00	0,10	0,00	0,00	0,00	0,00 %	0	0	-
35,00	0,00	0,10	0,00	0,00	0,00	0,00 %	0	0	-
36,00	0,00	0,10	0,00	0,00	0,00	0,00 %	0	0	-
37,00	0,00	0,10	0,00	0,00	0,00	0,00 %	0	0	-

Discussions et idées de trading en temps réel : négociez en toute confiance avec notre puissante plateforme.

Premium

Ventes

Strike	Achat	Vente	Dernier Prix	Point Médian	Var	Var %	Volume	INT OUVERT	Dernière Trans
20,00	0,00	0,10	0,00	0,00	0,00	0,00 %	0	0	-
21,00	0,00	0,10	0,00	0,00	0,00	0,00 %	0	0	-
22,00	0,00	0,10	0,00	0,00	0,00	0,00 %	0	0	-
23,00	0,00	0,10	0,00	0,00	0,00	0,00 %	0	0	-
24,00	0,00	0,10	0,00	0,00	0,00	0,00 %	0	0	-
25,00	0,00	0,10	0,00	0,00	0,00	0,00 %	0	0	-
26,00	0,00	0,10	0,00	0,00	0,00	0,00 %	0	0	-
27,00	0,00	0,10	0,00	0,00	0,00	0,00 %	0	0	-
28,00	0,00	0,10	0,09	0,09	0,00	0,00 %	0	99	-
29,00	0,75	0,90	0,00	0,825	0,00	0,00 %	0	0	-
30,00	1,75	1,90	0,00	1,825	0,00	0,00 %	0	0	-
31,00	2,75	2,90	0,00	2,825	0,00	0,00 %	0	0	-
32,00	3,70	3,90	0,00	3,80	0,00	0,00 %	0	0	-
33,00	4,70	4,90	0,00	4,80	0,00	0,00 %	0	0	-
34,00	5,70	5,90	0,00	5,80	0,00	0,00 %	0	0	-
35,00	6,70	6,90	0,00	6,80	0,00	0,00 %	0	0	-
36,00	7,70	7,90	0,00	7,80	0,00	0,00 %	0	0	-
37,00	8,70	8,90	0,00	8,80	0,00	0,00 %	0	0	-

Volume
% Gagnants
% Perdants

Symbole	Prix	Vol.
SCAGScage Future	US$ 0,8489 (196,61%)	92,75M
SPHLSpringview Holdings Ltd	US$ 5,38 (125,20%)	40,61M
NOTVInotiv Inc	US$ 0,1638 (89,15%)	1,07B
RMSGReal Messenger Corporation	US$ 1,809 (64,45%)	199,97M
STISolidion Technology Inc	US$ 35,50 (56,32%)	38,55M
NUWENewellis Inc	US$ 0,1625 (-62,30%)	50M
NYXHNyxoah SA	US$ 1,41 (-51,04%)	2,47M
CYPHCypherpunk Technologies Inc	US$ 0,5176 (-47,26%)	30,53M
TDICDreamland Ltd	US$ 0,2277 (-37,68%)	12,09M
FOFOHang Feng Technology Innovation Co Ltd	US$ 3,91 (-36,73%)	381,9k
NOTVInotiv Inc	US$ 0,1638 (89,15%)	1,07B
SNBRSleep Number Corporation	US$ 0,477 (36,25%)	305,13M
SMTKSmartKem Inc	US$ 0,419101 (30,97%)	232,19M
NVDANVIDIA Corporation	US$ 205,10 (-6,20%)	220,65M
RMSGReal Messenger Corporation	US$ 1,809 (64,45%)	199,97M

jimr1717

jimr1717 il y a 3 minutes

Has updated timeline 39Z-4 been updated?

researcher59

researcher59 il y a 4 minutes

SPCX - retail shares are not restricted, but Fidelity may limit access to futures IPOs for those who flip their shares in under 15 days.

The IPO may be oversubscribed, so if you ask for 50 shares you might only get 25.

https://www.businessinsider.com/spacex-ipo-fidelity

JimmyRich

JimmyRich il y a 5 minutes

🙏🏼🙏🏼🙏🏼 my friend

bbotcs

bbotcs il y a 5 minutes

INTU is near its 52-week low. If the perception among hedge fund managers and other institutional investors is that AI is going to hurt Intuit, it is going to stay down, imo.
The company needs a strong AI strategy.
Also, the dividend yield is not good. IMO, investors are not getting

Doc logic

Doc logic il y a 7 minutes

brazen22,

That is certainly one way of thinking. I personally don’t have a problem with that but there still remains the bigger picture to consider. In my view “the process” and the framework it is built on is the problem creating this kind of dilemma that all parties are required t

walterc

walterc il y a 7 minutes

th6565. what is your nationality?

jimr1717

jimr1717 il y a 10 minutes

“Although Wertheim & Co. no longer exists as an independent entity” ❌

Only Fools are Fooled

https://wertheimandcompany.com/transactions/

Top Penny

Top Penny il y a 11 minutes

Why not? Because you are short and nobody can make coin except you? Try again because you lose here pal!!!

Top Penny

Top Penny il y a 11 minutes

Within in the next 30 days IMO, soon trips are history for good!!!

Top Penny

Top Penny il y a 12 minutes

Lve

Lve il y a 14 minutes

What do you think the price will go to?

joe botts

joe botts il y a 14 minutes

prowler3701

prowler3701 il y a 14 minutes

Are we still in the quiet period?? LOL!!

Are we still the game changing, jaw dropping, next Lionsgate, tentpole movie, myflix tail that wags the dog, unbelievable movie distributor lol.

17 years of failure buffoon boy CEO.

Jack Wagon CEO!!

richme

richme il y a 14 minutes

Guess there is the problem of numbers in the clientele realm??

flipper44

flipper44 il y a 15 minutes

It’s been half a year since the ASM. It’s been over two and a half years since the MAA was submitted. It’s been two decades since the phase iii trial appeared on clinicaltrials.gov.

It’s great they are all around the world advocating for cancer vaccines, but we need an update. We

Lve

Lve il y a 15 minutes

DewDiligence

DewDiligence il y a 16 minutes

Berobenatide—dosed monthly—appears_competitive_with_weekly Zepbound/Wegovy in efficacy/tolerability—see slide 7 at the link in #msg-177679183.

US Market News

US Market News il y a 16 minutes

Lilly's triple agonist, retatrutide, drove substantial improvements in weight, A1C, knee osteoarthritis pain, and obstructive sleep apnea, demonstrating its remarkable potential to treat obesity and its complicationsJune 6, 2026 2:30 PM
PR Newswire (US)

DewDiligence

DewDiligence il y a 17 minutes

Berobenatide—dosed monthly—appears_competitive_with_weekly Zepbound/Wegovy in efficacy/tolerability—see slide 7 at the link in #msg-177679183.

janice shell

janice shell il y a 17 minutes

It’s about time!!

GeorgSchreiberEU

GeorgSchreiberEU il y a 20 minutes

Interesting development:

MSN has updated the name (not the ticker symbol) ... while OTC website still shows Natama

https://www.msn.com/en-us/money/stockdetails/fi-b19gfr?ocid=msedgntp&id=b19gfr

Rattlershehe

Rattlershehe il y a 22 minutes

Well, 55 his to skinny. Sigma pharmaceuticals was not in our wheelhouse. As an advisor to the company, the easiest way that I could say is. The whole Sigma thing went south as soon as the books needed to be audited. They did not want anyone in their business.
Methylene blue came into the pic

brazen22

brazen22 il y a 23 minutes

The “as quickly as possible” versus “as many as possible” framing has a problem.

If someone had GBM 2.5 years ago, I doubt they would view delay as acceptable because it might help reach more patients later. For the current GBM population, the fastest path matters.

Appr

mascale

mascale il y a 23 minutes

Qatar (royals) famous for recent lawful outcomes.

TightCoil

TightCoil il y a 24 minutes

Pulte Related? or Not?
IC3: Industry Alerts
Safeguarding Our Secrets
https://www.ic3.gov/CSA/2026/260603.pdf
June 3, 2026
Full Press Release

________________________________________

State Street SPDR Portfo...

Amundi MSCI World Small ...

Abacus Storage King

iShares ESG MSCI EM Lead...

Global X S&P 500 Covered...

Kraneshares Sse Star Mar...

Delayed Upgrade Clock

Assistance: support@advfn.fr

En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales

ADVFN

Vous avez déjà un compte? Connexion

Vous n'avez pas de compte ? Inscription

En m'inscrivant, je confirme avoir lu, compris et accepté les Conditions générales d'ADVFN et j'affirme etre un investisseur privé.